The gist

Adds pharmaceuticals and biologics to the list of technologies where US investment in Chinese firms is restricted or must be reported to the government.

Who wins, who loses

Wins: US drugmakers, national security hawks, domestic biologics manufacturers wanting less Chinese competition.

Loses: US pharma companies with Chinese licensing deals; Chinese biotech firms losing access to $136B in yearly cross-border deals.

What it does

Amends the Defense Production Act to cover drug discovery, clinical trials, and biologics manufacturing.

Adds licensing deals (not just investments) to prohibited transactions with covered foreign persons.

Orders Treasury to write detailed rules within 1 year, consulting Defense, Health, and Intelligence agencies.

Excludes agricultural biotech, industrial fermentation, and basic academic research from restrictions.

Why should I care?

Supporters say China's push to dominate drug innovation threatens US medicine supplies, like the rare earths and semiconductor dependencies already hurting America. Critics argue restricting pharma deals could slow new drug development, raise medicine prices, and cut US companies off from valuable research partnerships. Where do you land? Vote below and use "Tell Your Rep" to make sure your voice reaches Congress.